Home   >  
Angiogenesis/Protein Tyrosine Kinase
  • Jak/Stat Pathway
  • Wnt/Stem Cell
  • Epigenetics
∨
  >  
JAK

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

JAK

Chemical Structure Cat. No. Product Name CAS No.
Filgotinib maleate Chemical Structure
 BCP49095 Filgotinib maleate 1802998-75-9
Filgotinib maleate is a potent and selective JAK1 inhibitor under investigation for the treatment of rheumatoid arthritis (RA) and Crohn's disease.
Solcitinib Chemical Structure
 BCP23893 Solcitinib 1206163-45-2
Solcitinib is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis，systemic lupus erythematosus, ulcerative colitis.
Pacritinib citrate Chemical Structure
 BCP48998 Pacritinib citrate 1228923-42-9
Pacritinib Citrate is the citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity.
Ruxolitinib racemic Chemical Structure
 BCP25428 Ruxolitinib racemic 1160597-27-2
Ruxolitinib racemic is a Janus-associated kinase (JAK) inhibitor.
GDC-0214 Chemical Structure
 BCP47996 GDC-0214 1831144-46-7
GDC0214 is a potent, selective inhalable and lung-restricted inhibitor of JAK1 with IC50 of 8.52 nM, displays 6.3/704/28 fold selectivity over JAK2/JAK3/TYK2.
JAK-IN-5 hydrochloride Chemical Structure
 BCP48031 JAK-IN-5 hydrochloride 2751323-21-2
JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.
SJ10542 Chemical Structure
 BCP46974 SJ10542 SJ10542
SJ10542 is JAK2/3 PROTAC. SJ10542 displayed high selectivity over GSPT1 and other members of the JAK family and potency in patient-derived ALL cells containing both JAK2 fusions and CRLF2 rearrangements.
G5-7 Chemical Structure
 BCP46781 G5-7 939681-36-4
G5-7 is an orally active JAK2 inhibitor, selectively inhibits JAK2-mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 has the potential for glioma study.
SC99 Chemical Structure
 BCP46780 SC99 882290-02-0
SC99 is a selective inhibitor of JAK2-STAT3 activation.
AZD4205 Chemical Structure
 BCP46221 AZD4205 2091134-35-7
AZD4205 is a highly potent JAK1-selective kinase inhibitor with excellent preclinical pharmacokinetics with potential for further clinical development. JAK1 is part of the JAK1/signal transducer and activator of transcription (STAT) axis, which plays an important role in tumour escape from EGFR-targeted treatment.
123下一页末页共 98 条记录 1 / 10 页 
0086-13720134139